Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study

by Park, Keunchil, Janne, Pasi A., Kim, Dong-Wan, Han, Ji-Youn, Wu, Ming-Fang, Lee, Jong-Seok, Kang, Jin-Hyoung, Lee, Dae Ho, Cho, Byoung Chul, Yu, Chong-Jen, Pang, Yong Kek, Felip, Enriqueta, Kim, Hyunjin, Baek, Eunhye, Noh, Young Su
Published 2021

Asian thoracic oncology research group expert consensus statement on optimal management of stage III NSCLC

by Tan, Wan Ling, Chua, Kevin L. M., Lin, Chia-Chi, Lee, Victor H. F., Tho, Lye Mun, Chan, Anthony W., Ho, Gwo Fuang, Reungwetwattana, Thanyanan, Yang, James C., Kim, Dong-Wan, Soo, Ross A., Ahn, Yong Chan, Onishi, Hiroshi, Ahn, Myung-Ju, Mok, Tony S. K., Tan, Daniel S. W., Yang, Fan
Published 2020

Asian Thoracic Oncology Research Group (ATORG) expert consensus statement on MET alterations in NSCLC: Diagnostic and therapeutic considerations

by Ahn, Myung-Ju, Mendoza, Marvin Jonne L., Pavlakis, Nick, Kato, Terufumi, Soo, Ross A., Kim, Dong-Wan, Liam, Chong Kin, Hsia, Te-Chun, Lee, Chee Khoon, Reungwetwattana, Thanyanan, Geater, Sarayut, Chan, Oscar Siu Hong, Prasongsook, Naiyarat, Solomon, Benjamin J., Nguyen, Thi Thai Hoa, Kozuki, Toshiyuki, Yang, James Chih-Hsin, Wu, Yi-Long, Kam, Tony Shu, Tan, Daniel Shao-Weng, Yatabe, Yasushi
Published 2022